Navigation Links
Resverlogix Phase 1b/2a Study Meets Primary Endpoint
Date:8/25/2009

e including Drs. Nissen, Nicholls, Ballantyne, Taylor, and Kastelein for a Phase 2 study in cardiovascular disease patients which will be discussed in conjunction with the 2009 European Society of Cardiology Congress meeting in Barcelona, Spain. Resverlogix will be attending this important cardiovascular meeting and will communicate the results of the 28 day study to potential partners in greater detail, under confidentiality agreement. Furthermore, Dr. Norman Wong will present RVX-208 data on September 2, 2009 for Resverlogix during this meeting.

Since RVX-208 increases ApoA-I by production the Phase 1b/2a trial also examined early markers for ApoA-I production and reverse cholesterol transport such as pre-beta-HDL and Alpha1-HDL. Approximately half of the subjects had low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease.

"Showing in the Phase 1b/2a trial that we met the primary endpoint of increasing plasma ApoA-I in a safe and tolerable way is a huge milestone for Resverlogix," stated Donald J. McCaffrey, President CEO of Resverlogix. "There is an enormous unmet medical need in treating atherosclerosis and cardiovascular disease and the ApoA-I increases achieved by RVX-208 may just do that. We expect to update shareholders with further details of these activities later this year," added McCaffrey.

In addition to successfully completing the Phase 1b/2a trial, Resverlogix has also completed two arms of a Phase 1 BE (bio-equivalency) study for RVX-208 with the final arm being scheduled for completion in the end of the third quarter. The Phase 1 BE trial is a program designed to show that the newly formed capsule version of RVX-208 is equivalent to the earlier powder in a bottle version that has been used in all trials to date.

In unrelated news Mr. Kelly McNeill, Resverlogix CFO, will be leaving his current position effective September 18, 2009 and returning to Winnipeg for
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
2. Resverlogix Provides Quarterly Update
3. Resverlogix Board of Directors Update
4. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
5. Resverlogix Announces Closing of Debt Redemption
6. Resverlogix Eliminates Sixty Percent of Remaining Debt
7. Resverlogix Issues a Management Statement
8. Resverlogix Board of Directors Update
9. Resverlogix Notice of Conference Call & Webcast
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogixs Lead Drug Featured in Key Scientific Publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... announced today that it will release its full financial results ... on Thursday, March 12 th after market close, followed ... its financial results and business outlook. Participants should ... (412) 542-4135 (International) and request the InspireMD call. A live ...
(Date:3/6/2015)... March 6, 2015 BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... XIAPEX ®  in the EU, announced today that it ... at 8:30 a.m. ET on Friday, March 13, 2015 ... financial results and provide a corporate update. ...
(Date:3/6/2015)... 2015 Die ... der Assistance Publique - Hôpitaux de ... eine französische, gemeinschaftliche, randomisierte Kontrollstudie für die ... Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom ... Sorafenib behandelt wurden. Die Ergebnisse werden für ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Plant disease ... this summer at the Annual Meeting of The American ... to be released online now at APSnet.org/meet . ... for the meeting, to be held August 1-5, 2015 ... Special Sessions, Field Trips, Workshops, and committee meetings, all ...
Breaking Biology Technology:InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... Advanced Biofuels, LLC announced today that the United ... Butamax Patent Number 8,178,328. The ,328 patent covers ... from recombinant microorganisms at commercial scale.  These novel ... convert sugar to isobutanol. (Logo: ...
... the connection, if any, between sudden cardiac death and people ... In a comprehensive, 10-year UCSF study, researchers found patients ... times higher than the general population. "As part of ... instance of sudden death in San Francisco," said first author ...
... (Santa Barbara, Calif.) Imagine an LED light with 20 ... that can generate, transmit, and store data 100 times faster ... planet be if we could turn waste heat into electricity, ... more efficient, and more accessible? The (IEE) at ...
Cached Biology Technology:Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol 2Are people with HIV/AIDS more prone to sudden cardiac death? 2Are people with HIV/AIDS more prone to sudden cardiac death? 3Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 2Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 3Oracle chairman Jeff Henley makes $50 million gift to UC Santa Barbara 4
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... 7, 2014 Although brain growth slows as individuals ... for longer than others, creating new connections and remodeling ... in neuroscience, with implications for brain health and neurodegenerative ... of the adult brain that consume more fuel than ...
... Conservation of a protected or endangered species ... utilize to ensure the survival of threatened animals. ... to entire ecosystems. Currently, researchers at the University ... patterns of African forest elephants in protected and ...
... Jerusalem, January 7, 2014 -- Although drugs have been developed ... a condition which causes many brain disorders and nervous ... which these drugs work has not yet been fully explained. ... using baker,s yeast as a model, have deciphered the mode ...
Cached Biology News:Sugar-burning in the adult human brain is associated with continued growth, and remodeling 2Sugar-burning in the adult human brain is associated with continued growth, and remodeling 3MU researcher's study of African forest elephants helps guide research efforts in the US 2MU researcher's study of African forest elephants helps guide research efforts in the US 3Neurotransmitters resarch can promote better drugs for brain disorders 2Neurotransmitters resarch can promote better drugs for brain disorders 3
... The MX80 Series of positioning ... linear motor, ballscrew, leadscrew, micrometer, and ... construct high performance, cost-effective multi-axis systems. ... cross-roller bearings, encoder resolutions down to ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: